Phase II Study of MEDI4736 monotherapy or in combinations with Tremelimumab in Metastatic Pancreatic Ductal Carcinoma

Study identifier:D4198C00001

ClinicalTrials.gov identifier:NCT02558894

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Medical condition

Metastatic Pancreatic Ductal Adenocarcinoma

Phase

Phase 2

Healthy volunteers

No

Study drug

MEDI4736 monotherapy, tremelimumab+MEDI4736

Sex

All

Actual Enrollment

65

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 16 Nov 2015
Primary Completion Date: 15 Jun 2017
Study Completion Date: 15 Jun 2017

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2018 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria